1. Home
  2. CTNM vs CTGO Comparison

CTNM vs CTGO Comparison

Compare CTNM & CTGO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • CTNM
  • CTGO
  • Stock Information
  • Founded
  • CTNM 2009
  • CTGO 2009
  • Country
  • CTNM United States
  • CTGO United States
  • Employees
  • CTNM N/A
  • CTGO N/A
  • Industry
  • CTNM
  • CTGO Precious Metals
  • Sector
  • CTNM
  • CTGO Basic Materials
  • Exchange
  • CTNM Nasdaq
  • CTGO Nasdaq
  • Market Cap
  • CTNM 248.7M
  • CTGO 268.0M
  • IPO Year
  • CTNM 2024
  • CTGO N/A
  • Fundamental
  • Price
  • CTNM $12.40
  • CTGO $23.90
  • Analyst Decision
  • CTNM Strong Buy
  • CTGO Strong Buy
  • Analyst Count
  • CTNM 4
  • CTGO 1
  • Target Price
  • CTNM $22.75
  • CTGO $37.00
  • AVG Volume (30 Days)
  • CTNM 246.0K
  • CTGO 101.9K
  • Earning Date
  • CTNM 11-05-2025
  • CTGO 11-13-2025
  • Dividend Yield
  • CTNM N/A
  • CTGO N/A
  • EPS Growth
  • CTNM N/A
  • CTGO N/A
  • EPS
  • CTNM N/A
  • CTGO N/A
  • Revenue
  • CTNM N/A
  • CTGO N/A
  • Revenue This Year
  • CTNM N/A
  • CTGO N/A
  • Revenue Next Year
  • CTNM N/A
  • CTGO N/A
  • P/E Ratio
  • CTNM N/A
  • CTGO N/A
  • Revenue Growth
  • CTNM N/A
  • CTGO N/A
  • 52 Week Low
  • CTNM $3.35
  • CTGO $8.85
  • 52 Week High
  • CTNM $20.30
  • CTGO $24.70
  • Technical
  • Relative Strength Index (RSI)
  • CTNM 69.65
  • CTGO 63.59
  • Support Level
  • CTNM $11.46
  • CTGO $22.83
  • Resistance Level
  • CTNM $13.09
  • CTGO $24.70
  • Average True Range (ATR)
  • CTNM 1.02
  • CTGO 1.06
  • MACD
  • CTNM -0.07
  • CTGO 0.19
  • Stochastic Oscillator
  • CTNM 74.89
  • CTGO 79.38

About CTNM Contineum Therapeutics Inc. Class A Common Stock

Contineum Therapeutics Inc is a clinical stage biopharmaceutical company focused on discovering and developing novel, oral small molecule therapies for NI&I indications with high unmet need. Its internally-discovered drug candidates, PIPE-791 and PIPE-307, PIPE-791, is a novel, brain penetrant, small molecule inhibitor of the LPA1R in development for IPF and PIPE-307, is a novel, small molecule selective inhibitor of the muscarinic type 1 M1R, in development for depression and RRMS.

About CTGO Contango ORE Inc.

Contango Ore Inc operates in the United States. The company is engaged in the exploration of gold, silver, and copper ores in the State of Alaska. The company's focus is the exploration of a mineral lease with the Native Village of Tetlin whose governmental entity is the Tetlin Tribal Council for the exploration of minerals near Tok, Alaska. It has formed a joint venture to advance exploration of the Tetlin Property, which is prospective for gold and associated minerals. The Peak Gold JV Property is located in the Tetlin Hills and Mentasta Mountains of eastern interior Alaska. Its exploration projects are Lucky Shot, Johnson Tract, Eagle, Hona, Shamrock, and Triple Z.

Share on Social Networks: